Article

Trikafta therapy alters the CF lung mucus metabolome reshaping microbiome niche space

2021-06-04

Abstract excerpt

<h4>Background</h4> Novel small molecule therapies for cystic fibrosis (CF) are showing promising efficacy and becoming more widely available since recent FDA approval. The newest of these is a triple therapy of Elexacaftor-Tezacaftor-Ivacaftor (ETI, Trikafta®). Little is known about how these drugs will affect polymicrobial lung infections, which are the leading cause of morbidity and mortality among people with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 90ee974a-589b-5fe6-a0fd-a3bcacc00993
DOI: 10.1101/2021.06.02.21257731

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Trikafta therapy alters the CF lung mucus metabolome reshaping microbiome niche spaceDOI 10.1101/2021.06.02.21257731Read

Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapySemantic proximity Read

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.Semantic proximity Read

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosisSemantic proximity Read

High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic TherapySemantic proximity Read

Remodelling of cystic fibrosis respiratory microbiota in response to extended Elexacaftor–Tezacaftor–Ivacaftor therapySemantic proximity Read

Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-IvacaftorSemantic proximity Read

Elexacaftor/ivacaftor/tezacaftor effect on microbial density and the microbiome composition.Semantic proximity Read

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.Semantic proximity Read

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.Semantic proximity Read

Clinical Insights from Metagenomic Analysis of Sputum Samples from Patients with Cystic FibrosisSemantic proximity Read

Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the NewSemantic proximity Read

Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: an open-label proof-of-concept studySemantic proximity Read